Bronchodilator

Global Bronchodilators Market Report to 2027 - Featuring GlaxoSmithKline, Novartis, Pfizer and Sanofi Among Others - ResearchAndMarkets.com

Retrieved on:

Friday, November 4, 2022

Bronchodilators are medications used to treat patients suffering from long-term conditions of narrow and inflamed airways, such as asthma, emphysema, and chronic obstructive pulmonary disease (COPD).

Key Points:

Bronchodilators are medications used to treat patients suffering from long-term conditions of narrow and inflamed airways, such as asthma, emphysema, and chronic obstructive pulmonary disease (COPD).
They help relieve associated symptoms by relaxing the muscles around the airways or bronchi, clearing mucus from the lungs, and making breathing easier.
The publisher provides an analysis of the key trends in each sub-segment of the global bronchodilators market report, along with forecasts at the global, regional and country level from 2022-2027.
Our report has categorized the market based on indication, drug type and route of administration.

Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children

Retrieved on:

Monday, May 17, 2021

Respiratory therapy, Pulmonology, Clinical medicine, Health care, Asthma, Exhaled nitric oxide, Cough, Dupilumab, Bronchodilator, Respiratory tract, Vocal cord dysfunction

Dupixent also significantly improved overall asthma symptom control and reduced an airway biomarker of type 2 inflammation that plays a major role in asthma, called fractional exhaled nitric oxide (FeNO).

Key Points:

Dupixent also significantly improved overall asthma symptom control and reduced an airway biomarker of type 2 inflammation that plays a major role in asthma, called fractional exhaled nitric oxide (FeNO).
Despite treatment with current standard-of-care inhaled corticosteroids and bronchodilators, these children may continue to experience serious symptoms such as coughing, wheezing and difficulty breathing.
They also may require the use of multiple courses of systemic corticosteroids that carry significant risks.
Dupixent is also approved in the EU and Japan to treat certain adults with severe CRSwNP.

Chiesi Group receives European Marketing Authorization for Trimbow® inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) delivered through NEXThaler, an extrafine formulation fixed triple combination therapy fo

Retrieved on:

Wednesday, April 21, 2021

Pulmonology, Respiratory therapy, Health, XC2, Formoterol, Bronchodilator, Long-acting beta-adrenoceptor agonist, Chronic obstructive pulmonary disease, Inhaler

\xe2\x80\x9cChiesi triple therapy is today the first and only triple fixed combination treatment providing both pMDI and DPI devices as options for patients and physicians.

Key Points:

\xe2\x80\x9cChiesi triple therapy is today the first and only triple fixed combination treatment providing both pMDI and DPI devices as options for patients and physicians.
The Group is committed to becoming carbon neutral by the end of 2035.\nChiesi\xe2\x80\x99s triple therapy is an extrafine formulation, fixed triple combination, of beclometasone dipropionate (ICS) / formoterol fumarate (LABA) / glycopyrronium (LAMA).
Lancet 2016;\xc2\xa0388:\xc2\xa0963\xe2\x80\x93973.\nVestbo\xc2\xa0J,\xc2\xa0Papi\xc2\xa0A,\xc2\xa0Corradi\xc2\xa0M,\xc2\xa0et al.\xc2\xa0Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Lancet 2017;\xc2\xa0389:\xc2\xa01919\xe2\x80\x931929.\nPapi\xc2\xa0A,\xc2\xa0Vestbo\xc2\xa0J,\xc2\xa0Fabbri\xc2\xa0L,\xc2\xa0et al.\xc2\xa0Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.

Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution and Discharge after Single IND Emergency Use Authorization of Lenzilumab™

Retrieved on:

Friday, October 2, 2020

Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Respiratory diseases, Medical specialties, Pulmonology, Respiratory physiology, Zoonoses, Coronavirus disease, Occupational safety and health, Acute exacerbation of chronic obstructive pulmonary disease, Chronic obstructive pulmonary disease, Severe acute respiratory syndrome, Acute respiratory distress syndrome, Bronchodilator

The case report, titled COVID-19 associated chronic ARDS successfully treated with lenzilumab is available at: https://osf.io/xusr9/ .

Key Points:

The case report, titled COVID-19 associated chronic ARDS successfully treated with lenzilumab is available at: https://osf.io/xusr9/ .
The patient tested positive for SARS-CoV-2 and was admitted to the ICU in March 2020 for COVID-19 and put on respiratory isolation.
The patient was treated with steroids, broad spectrum antibiotics for community acquired pneumonia and bronchodilators for possible COPD exacerbation and hydroxychloroquine with zinc.
You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Surge in Demand for Anti-asthmatics and COPD Drugs due to Coronavirus, Reports TBRC

Retrieved on:

Tuesday, April 28, 2020

Pulmonology, Respiratory therapy, Respiratory diseases, Medicine, Chronic lower respiratory diseases, Chronic obstructive pulmonary disease, Asthma, Bronchodilator, COPD: Journal of Chronic Obstructive Pulmonary Disease, Obstructive lung disease

This has created a sudden rise in demand for anti-asthmatics and COPD drugs.

Key Points:

This has created a sudden rise in demand for anti-asthmatics and COPD drugs.
Request A Free Sample Of The Anti-Asthmatic And COPD Drugs Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=2417&type=smp
The anti-asthmatics and COPD drugs market consists of sales of anti-asthmatics and COPD drugs by entities (organizations, sole traders and partnerships) that manufacture anti-asthmatics and COPD drugs which are used to prevent and treat asthma and chronic obstructive pulmonary disease (COPD).
The anti-asthmatics and COPD drug industry includes establishments that manufacture anti-asthmatics and COPD drugs such as bronchodilators, anti-inflammatory drugs, monoclonal antibodies and combination drugs.
The anti-asthmatics and COPD drugs market is segmented by class into bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs.

Allergy Medicine Growing by 232% as Hospitals and Consumers Drive Demand - Albuterol Being Used in Hospitals as an Alternative to Nebulizers for Patients With COVID-19 - ResearchAndMarkets.com

Retrieved on:

Wednesday, April 22, 2020

Health, Pharmaceutical, Medicine, Health, Respiratory therapy, RTT, Dosage forms, Medical equipment, Pulmonary function testing, Ventolin, Nebulizer, Bronchodilator, Salbutamol, Asthma

This has created huge demand for over-the-counter and prescription allergy medications as consumers stock up on necessary medicines.

Key Points:

This has created huge demand for over-the-counter and prescription allergy medications as consumers stock up on necessary medicines.
The United States has seen a sharp rise in demand for Albuterol from both hospitals and consumers.
Albuterol, sold under the brand names Ventolin and Pro Air, is a bronchodilator commonly used as a rescue treatment for asthma attacks.
It is also being used in hospitals as an alternative to nebulizers for patients with COVID-19 to reduce the risk of aerosolizing the virus.

Premier Inc. Data Shows Drugs Essential to Providing Care for COVID-19 Patients Quickly Slipping into Shortage

Retrieved on:

Wednesday, April 1, 2020

Premier surveyed its members and found that active shortages are far more pervasive in the acute care setting, where 70 percent of acute care respondents report at least one shortage for COVID-19 drugs.

Key Points:

Premier surveyed its members and found that active shortages are far more pervasive in the acute care setting, where 70 percent of acute care respondents report at least one shortage for COVID-19 drugs.
Antimalarial drugs were the most commonly reported shortage (70 percent of hospital respondents), followed by bronchodilators (65 percent), antibiotics (40 percent), antivirals (38 percent) and sedatives (35 percent).
Premier created the following set of recommendations that, if acted upon quickly, will either prevent or ease shortages for COVID-19 drugs.
With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.

Bronchodilators Market to Reach $41.48 Bn, Globally, by 2026 at 5.2% CAGR: Allied Market Research

Retrieved on:

Monday, March 2, 2020

Pulmonology, Respiratory therapy, Chronic lower respiratory diseases, Medicine, Health, Bronchodilator, Pulmonary function testing, Respiratory physiology, Chronic obstructive pulmonary disease, Asthma

According to the report, the global bronchodilators industry was estimated at $27.58 billion in 2018 and is expected to hit $41.48 billion by 2026, registering a CAGR of 5.2% from 2019 to 2026.

Key Points:

According to the report, the global bronchodilators industry was estimated at $27.58 billion in 2018 and is expected to hit $41.48 billion by 2026, registering a CAGR of 5.2% from 2019 to 2026.
Rise in prevalence of asthma and COPD and increase in government initiatives drive the growth of the global bronchodilators market.
On the other hand, several side effects associated with bronchodilators hamper the growth to some extent.
Based on drug type, the anticholinergics segment held the highest share in 2018, garnering nearly half of the global bronchodilators market.

Bronchodilators Market to Reach $41.48 Bn, Globally, by 2026 at 5.2% CAGR: Allied Market Research

Retrieved on:

Monday, March 2, 2020

According to the report, the global bronchodilators industry was estimated at $27.58 billion in 2018 and is expected to hit $41.48 billion by 2026, registering a CAGR of 5.2% from 2019 to 2026.

Key Points:

According to the report, the global bronchodilators industry was estimated at $27.58 billion in 2018 and is expected to hit $41.48 billion by 2026, registering a CAGR of 5.2% from 2019 to 2026.
Rise in prevalence of asthma and COPD and increase in government initiatives drive the growth of the global bronchodilators market.
On the other hand, several side effects associated with bronchodilators hamper the growth to some extent.
Based on drug type, the anticholinergics segment held the highest share in 2018, garnering nearly half of the global bronchodilators market.

Reduced Inhaler Use is Safe for Infants with Bronchiolitis

Retrieved on:

Monday, January 13, 2020

Medicine, Medical specialties, Medical equipment, Health, Bronchiolitis, Pediatrics, RTT, Respiratory therapy, Bronchodilator, Nasal cannula, Cannula, Bronchiole

A multidisciplinary team of researchers from Children's Hospital of Philadelphia (CHOP) redesigned the hospital's standard treatment for the infection and reduced albuterol use without compromising care.

Key Points:

A multidisciplinary team of researchers from Children's Hospital of Philadelphia (CHOP) redesigned the hospital's standard treatment for the infection and reduced albuterol use without compromising care.
The AAP updated its bronchiolitis guidelines in 2014, recommending against the use of bronchodilators like albuterol in typical patients with bronchiolitis.
The team measured patient admission rates, length of stay and revisit rates and found the reduced albuterol use did not impact those metrics.
"The next step for improving bronchiolitis care at CHOP is focusing on the use of the high-flow nasal cannula, an emerging therapy for infants with severe bronchiolitis."